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The collagen VI-related muscular dystrophies in people include a broad spectrum of diseases 
ranging from the severe Ullrich congenital muscular dystrophy to the mild type Bethlem. 
Clinical features are attributable to both muscle and connective tissue and include progressive 
muscle weakness and respiratory failure, hyperlaxity of distal joints, and progressive contracture 
of large joints. Here we describe two different COL6A3 pathogenic variants in Labrador 
Retriever dogs that result in autosomal recessive or autosomal dominant congenital myopathies 
with hyperlaxity of distal joints and joint contracture, similar to the condition in people.  
 
 







 The collagen VI-related muscular dystrophies in people include a broad spectrum of 
severities ranging from the severe Ullrich congenital muscular dystrophy to the mild type 
Bethlem [1]. Ullrich congenital muscular dystrophy is rare but is among the most common type 
of congenital muscular dystrophies in several populations [1,2]. In northern England, the 
collagen VI-related myopathies have a point prevalence of 0.9 patients for 100,000 individuals 
[3]. These diseases are caused by both dominantly and recessively acting mutations in the three 
major α-chains encoded by the collagen VI genes COL6A1, COL6A2 and COL6A3, which 
associate in equal stoichiometry to form a heterotrimeric monomer followed by further assembly 
to a tetrameric structure, which is then secreted into the extracellular matrix by fibroblastic cells 
in muscle and other connective tissues such as tendon. Clinical features are thus attributable to 
both muscle and connective tissue and include progressive muscle weakness, hyperlaxity of 
distal joints, progressive contracture of large joints, and respiratory failure in the more severe 
forms. In dogs, descriptions of collagen VI-related diseases have been limited to a recessively 
acting nonsense variant in COL6A1 described in young Landseer Newfoundland dogs [4] and a 
clinical, pathological and immunohistochemical description of subsarcolemmal collagen VI 
deficiency in a young Labrador Retriever without genetic confirmation [5].   
  
 Previously described inherited myopathies in young Labrador Retriever dogs include 
dystrophin deficient muscular dystrophy [6,7], X-linked myotubular myopathy [8,9], 
centronuclear myopathy [10,11], a congenital myasthenic syndrome attributable to a COLQ 
variant [12], and the above-mentioned sarcolemmal-specific collagen VI deficiency [5]. Here we 




muscular dystrophy in a recently ascertained small family of Labrador Retrievers and in the case 
of previously recognized sarcolemmal-specific collagen VI deficiency [5].  
 
2. Methods 
2.1 Animals:  
 Dogs in this report were evaluated as clinical cases by practicing veterinary specialists. 
Owner approval for all diagnostic evaluations was obtained and IACUC approval was not 
required for evaluating diagnostic tissue specimens.  
 
2.2 Histopathology and Immunofluorescence Staining 
 Unfixed muscle biopsies were either wrapped in a saline-dampened gauze sponge and 
chilled, or immersion-fixed in 10% neutral buffered formalin. Biopsies were shipped by an 
overnight service under refrigeration to the Comparative Neuromuscular Laboratory at the 
University of California, San Diego, immediately flash frozen in isopentane pre-cooled in liquid 
nitrogen, and stored frozen at -80°C until further processed. Cryosections were stained or reacted 
with a standard panel of histochemical stains and reactions [13]. Additional cryosections (8 µm) 
were cut and stained by indirect immunofluorescence as previously described [14]. Sections 
were incubated with monoclonal or polyclonal antibodies against collagen VI (gift of Eva 
Engvall, 3G7, direct apply) [15], laminin α2 (gift of Eva Engvall, 1B4, direct apply) [16], and α-
sarcoglycan (gift of Eva Engvall, 1:200) [17]. Fixed biopsies were paraffin embedded and 
processed by standard procedures.  
 




 Skin biopsies were collected using a punch biopsy procedure, placed in transport media 
(10% FBS/1% P/S/DMEM with ascorbic acid (final concentration 50 ng/µl) and shipped by an 
overnight service to the laboratory (NIH). Upon receipt, cells were cultured for 4 days in the 
same media until 80% confluence in an 8-well chamber slide. Cells were blocked at RT for 30 
minutes in10% FBS/PBS with or without 0.1% triton X-100 (cell permeabilizing agent) to detect 
intracellular retention or extracellular matrix, respectively. Primary antibodies (COL6 rabbit 
antibody 1:500, ab6588, Abcam) were incubated at RT for 1.5 hr in 10% FBS/PBS followed by 
secondary antibodies (Alexa Fluor 488 goat anti-rabbit 1:500 (A11034, Invitrogen) at RT for 1 
hr in the dark. After washes, the cells were incubated with DAPI 1:1000 at RT for 1-2 min in the 
dark. Following washes, the slides were cover slipped and stored at 4°C in the dark until 
analysis.  
 
2.4 Whole Genome Sequencing and Variant Analysis: Case 1   
 Genomic DNA was extracted from muscle biopsies using the DNEasy kit standard 
protocol (Qiagen). Approximately 3 µg of DNA from each dog was submitted for library 
preparation and whole genome sequencing at Genewiz (Plainfield, NJ) using a 150 bp paired-end 
read configuration in separate lanes of an Illumina HiSeq 4000 high-throughput sequencing 
system. These reads have been made publicly available at NCBI’s Short Read Archive at 
http://www.ncbi.nlm.nih.gov/bioproject/560083. Variant calling from WGS data was performed 
using a standardized bioinformatics pipeline for all samples as described previously [18].  
 Heterozygous or homozygous variants present in the probands were initially filtered 
against a population of 307 dogs of 48 different breeds whose entire genomes were sequenced as 




20 Standard Poodles, 19 Miniature Schnauzers, 19 Great Danes, 13 Cavalier King Charles 
Spaniels, 12 Siberian Huskies, 11 Dachshunds, 11 Golden Retrievers, 10 Miniature Poodles, 10 
Scottish Deerhounds, 10 Labrador Retrievers, and 116 dogs of 36 additional breeds. Whole 
genome sequences from these dogs were processed using a similar bioinformatics pipeline as 
described above. Variants that passed our filtering step and were unique to the proband were 
annotated using Variant Effect Predictor 91 [19], and evaluated based on the severity of the 
predicted effect. Variants we considered most impactful included frameshifts, in-frame insertions 
and deletions, premature-start, stop-gained, missense, and splice region changes. Candidate 
variants were then secondarily compared to those of control genomes from 640 dogs and 8 
wolves found in the Dog Biomedical Variant Database Consortium (DBVDC) database and 668 
dogs and 54 wild canids [20]. 
 
2.5 RNA and DNA isolation – Case 2  
 RNA and DNA were isolated from the frozen archived muscle biopsy (biceps femoris) of 
Case 2. Sectioning of the muscle biopsy was carried out on a Microm HM550 cryostat 
(ThermoFisher Scientific, Waltham, MA). Thirty sections (10 um thickness each) of the muscle 
biopsy were collected in a pre-cooled microcentrifuge tube and were homogenized in one mL of 
Trizol reagent (ThermoFisher Scientific). Following the first phase separation, RNA was isolated 
from the aqueous phase, and DNA was isolated from the phenol/chloroform phase, according to 
manufacturer’s instructions. For the control dog, RNA and DNA were isolated from cultured 
dermal fibroblasts. After reaching confluence, cells were detached from the dish using 0.05% 




1x phosphate buffered saline (ThermoFisher Scientific), the cell pellet was homogenized in one 
mL of Trizol reagent. Nucleic acid isolation was then carried out as described above. 
 
2.6 Mutation screening 
 Complementary DNA (cDNA) was prepared from one ug of RNA, using random primers 
and a Superscript III reverse transcriptase protocol, following manufacturer’s protocol 
(ThermoFisher Scientific). PCR amplification from the cDNA samples was carried out to screen 
the collagenous domains of COL6A1, COL6A2, and COL6A3 for the presence of potential 
pathogenic exon skips, using multiple overlapping PCR reactions to cover the entire regions, and 
from gDNA to screen the COL6A3 exon 16 region for genomic mutations. PCRs were performed 
with the Advantage 2 PCR enzyme system (Takara Bio USA, Mountain View, CA), and the 
primers used are listed in Table S1. The cycling parameters used were as followed: initial 
denaturation at 95˚C for 1 min, 5 cycles of 95˚C for 30 sec, and 68˚C for 1 min, then 5 cycles of 
95˚C for 30 sec, 64˚C for 30 sec, and 68˚C for 45 sec, followed by 25 or 30 cycles of 95˚C for 30 
sec, 56˚ or 58˚C for 30 sec, and 68˚C for 45 sec, and a final extension at 68˚C for 1 min. PCR 
products were run on a 2.5% agarose gel containing SYBR Safe DNA Gel Stain (ThermoFisher) 
in Tris-Acetate EDTA (TAE) buffer using the RunOne electrophoresis system (Embi Tec, San 
Diego, CA). Fragments were detected using the ChemiDoc XRS+ molecular imager (Bio-Rad, 
Hercules, CA). 
2.7 Genotyping 
 DNA samples of 105 Labrador Retrievers available in the University of Minnesota 
Canine Genetics Laboratory were genotyped for the COL6A3 exon 10 and exon 16 variants via 




primers as follows: For COL6A3 exon 10 forward primer 5’-AAGTCATACCTGGCCGTGAG-
3’ and reverse primer 5’-GTCAGCTGAGGCACAGAGG-3’ that produce a 399 bp amplicon, 
and for COL6A3 exon 16  forward primer 5’-GGAAAATCACTGGAAATGCAA-3’ and reverse 
primer 5’-GGGGAGATGCTTGAAGGTAG-3’ that produce a 231 bp product.  PCR products 
were sequenced at Genewiz (South Plainfield, NJ). 
  
3. Results 
3.1 Clinical Evaluation of Two Cases of Congenital Myopathy in Labrador Retrievers 
 Case 1: A 6-month-old male Labrador Retriever was evaluated for a 2-month history of 
angular limb deformity and carpal hyperextension (Figure 1A). The serum creatine kinase (CK) 
activity was mildly increased at 866 IU/L (reference 10-200 IU/L). A neuromuscular disease was 
suspected and a clinical evaluation including muscle biopsies was performed. The dog was from 
a litter of 7 puppies resulting from a cross of 2 phenotypically normal dogs (Figure 1C). Two 
puppies (one male and one female) were described as affected, 4 were phenotypically normal 
and 1 puppy died at birth. The dam was the aunt of the sire.  
 Case 2: An 11-month-old female neutered Labrador Retriever was presented for 
evaluation of progressive gait abnormalities and carpal and tarsal hyperextension of 6 months 
duration (Figure1B). As the dog was adopted from a rescue shelter, previous history and 
information on the parents and littermates was not available. The clinical details, histopathology 
and immunostaining of muscle from this dog have been previously described [5].   
 




Biopsies were collected from the biceps femoris, quadriceps and triceps brachii muscles 
of Case 1 by an open biopsy procedure under general inhalational anesthesia. Similar 
pathological changes were observed in all three muscles including excessive variability in 
myofiber size, mild endomysial fibrosis and occasional internalized nuclei (Figure 2A). 
Immunofluorescence staining of the biceps femoris and triceps muscles for localization of 
collagen VI showed an absence of staining in both the interstitium and sarcolemma compared to 
archived control muscle (Figure 2B). An antibody against α-sarcoglycan highlighted the outline 
of the myofibers in both the case and control muscles (Figure 2B).  For comparison, similar 
myopathic changes were present histologically in the biopsies from Case 2 [5]. However, 
immunofluorescence staining in Case 2 for localization of collagen VI showed that staining was 
present in the interstitium but not on the sarcolemma, indicative of a sarcolemmal-specific 
collagen VI deficiency [5].  
   
Fibroblasts isolated from a skin biopsy of Case 1 were cultured and stained to assess for 
collagen VI secretion and matrix assembly. Under normal staining conditions (i.e. without cell 
permeabilization), we observed that fibroblasts from Case 1 did not produce any formed collagen 
VI matrix, as opposed to a control sample in which the matrix was visible (Figure 2C, left 
panels). Absence of collagen VI reactivity in matrix cultures is typical for recessive mutations 
that cause Ullrich congenital muscular dystrophy [1]. Collagen VI immunostaining with cell 
permeabilization can detect if collagen VI tetramers are retained intracellularly as a result of 
dominant-negatively acting mutations. Here, fibroblasts from Case 1 showed no retention 





3.3 Genome Sequencing and Variant Analysis on Case 1 
 COL6A3 has 43 exons, encoding 3169 amino acids (Figure 3A). Initial screening of the 
triple helical domains of COL6A1, COL6A2, and COL6A3 of Case 1 by cDNA sequencing did 
not identify any pathogenic mutations (data not shown). However, whole genome sequencing 
identified a premature stop codon variant (chr25:48,014,962G>A; c.4726C>T; p.R1576*) in 
exon 10 of the COL6A3 gene (Figure 3A, B) which would truncate about half the 
protein.  Pathogenicity is also highly supported by the fact that this variant is not found in any of 
the > 1300 dogs across WGS databases (DBVDC, [19], UMN internal WGS database). Follow-
up analysis of the dam and sire showed that both were heterozygous for this variant (Figure 3B) 
and clinically normal. An affected female littermate was also homozygous mutant, while an 
unaffected male littermate was heterozygous (Figure 1C), demonstrating that the genotypes 
segregated with the phenotype in this pedigree and were consistent with a recessive collagen VI-
associated muscular dystrophy. No carriers of the R1576* variant were found in a population of 
105 unrelated Labrador Retrievers.     
 
3.4 Genome Sequencing and Variant Analysis on Case 2 
 The clinical diagnosis in Case 2 of sarcolemmal-specific collagen VI deficiency [5] 
prompted the search for the causative mutation in this dog. The triple helical domains of 
COL6A1, COL6A2, and COL6A3 were screened by cDNA sequencing. Sequencing results for 
COL6A1 and COL6A2 were negative (data not shown). In COL6A3, we detected the presence of 




presence of two mRNA species: one normal and one lacking exon 16 ('16) (Figure 3C). To 
confirm the expression of these two species in muscle tissue from Case 2, we separated by size 
reverse-transcription PCR (RT-PCR) products on agarose gel (Figure 3D), and sequenced the 
products isolated from the gel. Sequencing confirmed the skipping of exon 16 in the shorter 
products, as shown by the junction of exon 15 to exon 17 (Figure 3E). In addition, the seemingly 
equal expression levels of normal (WT) and '16 mRNA (Figure 3D) were suggestive of the 
presence of a heterozygous mutation affecting exon 16 splicing, such as splice site mutations or 
genomic deletions.  
 To identify the genomic variant underlying the exon 16 skipping, we sequenced genomic 
DNA in the vicinity of exon 16. The sequencing chromatograms showed a heterozygous guanine 
to adenine variant at the first position of intron 16 (chr25:48,007,994C>T; c.6210+1G>A), 
changing the immediate splice donor site motif from CCgt to CCat (Figure 3F). COL6A3 exon 
16 is 54 nucleotides in length, and its removal from the mature messenger RNA (mRNA) does 
not affect the reading frame, thus suggesting that this splice variant is translated and acting in a 
dominant manner because it would be predicted to be assembled into the tetrameric state. This 
exon is located at the N-terminus of the triple helical domain, a hot-spot for dominant-negative 
assembly-competent mutations [1] (Figure 3A). Indeed, in-frame skipping of COL6A3 exon 16 is 
one of the more common consequences of dominantly acting mutations identified in individuals 
with Ullrich congenital muscular dystrophy [21,22], and has been shown to act as dominant-
negative [21-23]. The genetic findings in Case 2 were thus consistent with a pathogenic COL6 
mutation acting as a dominant-negative and causing the sarcolemmal-specific COLVI deficiency 




found in the population of 105 unrelated Labrador Retrievers, nor in any of the > 1300 dogs 
across WGS databases (DBVDC, [19], UMN internal WGS database).  
 
4. Discussion  
 Here we report two COL6A3 mutations causing a muscular dystrophy in Labrador 
Retriever dogs that has resemblance to human COLVI-related muscular dystrophies, including 
Ullrich type congenital muscular dystrophy. The clinical presentations in affected Labrador 
Retrievers with variants in COL6A3 were similar to that of human patients in that there was an 
early onset of joint deformities, laxity at 5 to 6 months of age and slow progression lasting into 
adulthood. Case 1 is still alive at this writing (at 31 months of age) and the dog has maintained 
ambulation. By 50 months post-diagnosis, Case 2 showed significant bilateral symmetrical 
atrophy of the appendicular and masticatory muscles, and corneal opacities. The dog became 
unable to support weight and was euthanized 80 months post-diagnosis.  
 We identified both autosomal recessively and dominantly acting mutations in COL6A3, 
closely resembling the underlying genetic mechanism in human patients. Specifically, the 
heterozygous exon 16 (COL6A3) variant identified in Case 2 in its consequence is identical to 
human mutations with the same exon skipping outcome that have been shown to act via a 
dominant-negative mechanism leading to a severe Ullrich type phenotype and typically arise de 
novo. In fact, COL6A3 skipping of exon 16 is a recurrent human dominant Ullrich mutational 
mechanism [21,22]. In particular, the c.6210+1G>A mutation that was found as the cause for the 
exon 16 skip in Case 2 is the same mutation that is recognized as the most frequent cause of exon 
16 skips in patients in the literature [21, 22], and in public databases (ClinVar, LOVD Leiden 




were not available for genotyping. As this is a relatively common mutation class in human 
patients, we have recently demonstrated proof-of principle for the therapeutic validity of mutant 
allele-specific knockdown of the exon 16 (COL6A3) deleted transcript using RNA interference 
[23]. 
 In Case 1, the homozygous premature stop codon (p.R1576*) variant in exon 10 of the 43 
exon (3169 amino acid) COL6A3 gene would result in truncation of approximately half of the 
protein upstream of the triple helical domain, which would be predicted to be nonfunctional and 
not capable of assembly.  Premature termination mutations are also frequently associated with 
non-sense mediated mRNA decay, resulting in no translation into protein. The fibroblast staining 
revealed a complete absence of a formed collagen VI matrix which is consistent with both of 
these mechanisms and supportive of a complete Null situation. Of interest, this variant was 
reported in a single patient [24], and in a public database (ClinVar). In both instances the variant 
was identified in a heterozygous state. The consequence of the variant is significantly different 
however: in dogs, Arg1576 is encoded by the codon “CGA”, whereas in human, it is encoded by 
“CGG”. In both cases, nucleotide 4726 (NM_004369.3 in human) corresponds to the first 
nucleotide of the codon, but while it produces a termination codon in the dog (CGA>TGA), in 
the human it results in a tryptophan codon (CGG>TGG). As a consequence, p.R1576W is still 
classified as a variant of unknown significance, and it is still to be determined whether it is 
pathogenic. Nevertheless, it is noteworthy that those two particular genomic locations (c.4726C 
and c.6210+1G) are mutation targets in the different species.  
 The clinical presentation was similar in both affected Labrador Retrievers with mutations 
in COL6A3 but differed from that previously reported in Landseer dogs with a mutation in 




few weeks of age with euthanasia by 5 to 15 months of age. Laxity of distal joints and angular 
contractures of proximal joints as found in the Labradors were not described in the Landseers, 
although the stifle and tarsal joints were held in a slight flexed position. A decreased range of 
motion of the joints was described [4] as opposed to hyperlaxity. The phenotypic differences 
between the two breeds of dogs with COL6 mutations is also in contrast to what is found in 
human patients, as the clinical presentation and severity is independent of whether the mutations 
lie in COL6A1, COL6A2, or COL6A3. These phenotypic differences may be a result of the 
different genetic backgrounds, the effect of modifier genes, or the consequence of compensatory 
mechanisms such as the expression of additional collagen VI chains that could more effectively 
compensate for the lack of α3(VI) than of α1(VI) chains [25,26]. 
 
Conclusions 
 This study expands the spectrum of congenital neuromuscular diseases affecting dogs 
with direct correlations to the corresponding human conditions. Indeed, both autosomal recessive 
and dominant mutations in genes encoding collagen VI that occur in humans have also been 
confirmed in dogs. Phenotypic differences between dog breeds may be a result of differences in 
genetic background or the effect of modifying genes. It is likely that the pace of discovery of 
novel mutations underlying canine neuromuscular disorders will continue to increase as whole 
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Figure Legends 
Figure 1. Clinical signs of congenital muscular dystrophy in two Labrador Retrievers.  (A) 
Image of a 6 month-old male (Case 1) showing carpal hyperextension and limb deformities.  (B) 
Image of a 11 month-old female (Case 2) showing carpal and tarsal hyperextension.   
 (C) Limited pedigree of Case 1 (identified by the red asterisk). Genotypes at the COL6A3 
c.4726C>T (p.R1576*) locus are indicated for individuals tested.  
  
Figure 2. Abnormal muscle histology and absence of collagen VI staining in Case 1. (A) 
Hematoxylin and eosin (H&E) staining of a muscle biopsy section from Case 1 showing a 
dystrophic phenotype including excessive variability in myofiber size, endomysial fibrosis and 
excessive internal nuclei. Scale bar = 50 µm.  (B) Muscle biopsy sections co-stained for collagen 
VI (green) and α-sarcoglycan (red). Scale bar = 50 µm.  (C) Primary dermal fibroblasts cultured 
and stained for collagen VI (green), and nuclei (DAPI, blue), in absence (-) or presence (+) of a 





Figure 3. Muscular dystrophy in Labrador retriever dogs caused by mutations in COL6A3. 
(A) Schematic of the main collagen a3(VI) chain protein domains in dog, and the relative 
positions of the recessive and dominant mutations found in the affected Labrador retriever dogs 
Case 1 and Case 2, respectively. aa = amino acid. (B) Alignments of exon 10 sequences of Case 
1, the sire, the dam, and a control obtained by Sanger sequencing of a PCR amplicon. The box 
indicates the location where a homozygous C nucleotide in the control genome is replaced with a 
homozygous T nucleotide in the case. Both the sire and dam are heterozygous. The mutation 
changes the codon for an arginine residue (CGA) to TCA to the stop codon (TGA).  (C) 
Complementary DNA (cDNA) forward (-F) and reverse (-R) sequencing chromatograms of a 
control dog and of Case 2, spanning exon 16 of the COL6A3 gene. CDS = coding sequence.  (D) 
cDNA amplification and electrophoresis of COL6A3 transcripts. The fragments in Case 2 lane 
show an approximately equal expression of normal transcripts (wild-type, WT) and transcripts 
lacking exon 16 (∆16), which is 54 nucleotides in size.  (E) Sequencing chromatograms of the 
PCR fragments isolated from the electrophoresis gel in (B) showing the junction of exon 15 to 
exon 17.  (F) Sequencing chromatograms from genomic DNA show that Case 2 is a 
heterozygous carrier of the COL6A3 c.6210+1G>A mutation.  
  
Supplementary Table S1. Primers used in this study for variant discovery.   
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